ArticleWorld journal of gastrointestinal surgery2025
Association between hepatitis B virus markers and liver fibrosis staging in patients with chronic hepatitis B.
Article in World journal of gastrointestinal surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExisting assessment systems for chronic hepatitis B (CHB)-associated liver fibrosis (LF) exhibit insufficient accuracy, thereby requiring further improvements.
aimTo investigate the association of LF staging with hepatitis B core antibody (HBcAb), hepatitis B virus DNA (HBV-DNA), and hepatitis B surface antigen (HBsAg) in patients with CHB.
methodsWe selected 120 patients with CHB receiving treatment in Hangzhou Linping District First People's Hospital from January 2020 to June 2024. Participants were allocated into the mild (F0-F1,
resultsMarkedly increased HBcAb and notably decreased HBV-DNA and HBsAg were observed in moderate-to-severe cases
conclusionHBcAb is negatively correlated with HBV-DNA and HBsAg but positively associated with LF staging. All three markers are valuable in assessing LF staging, and their combined use presents the highest diagnostic efficacy. Importantly, a high HBcAb/low HBV-DNA profile markedly increased fibrosis progression risks in CHB-affected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.